{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:37:08Z","timestamp":1786527428128,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05340-9","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:04:51Z","timestamp":1786525491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-4776","authenticated-orcid":false,"given":"Leonardo","family":"Spatola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Oddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Zeiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"19","key":"5340_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2025.0310","volume":"333","author":"FT Chebib","year":"2025","unstructured":"Chebib FT, Hanna C, Harris PC, Torres VE, Dahl NK (2025) Autosomal dominant polycystic kidney disease: a review. JAMA 333(19):1708\u20131719. https:\/\/doi.org\/10.1001\/jama.2025.0310","journal-title":"JAMA"},{"issue":"15","key":"5340_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138724","volume":"5","author":"S Lavu","year":"2020","unstructured":"Lavu S, Vaughan LE, Senum SR et al (2020) The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight 5(15):e138724. https:\/\/doi.org\/10.1172\/jci.insight.138724","journal-title":"JCI Insight"},{"key":"5340_CR3","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"key":"5340_CR4","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930\u20131942. https:\/\/doi.org\/10.1056\/NEJMoa1710030","journal-title":"N Engl J Med"},{"key":"5340_CR5","doi-asserted-by":"crossref","unstructured":"Devuyst O, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le , Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, et al; Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. 2025 Kidney Disease: Kidney Int 107 (2S):","DOI":"10.1016\/j.kint.2024.07.009"},{"issue":"5","key":"5340_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","volume":"7","author":"X Zhou","year":"2022","unstructured":"Zhou X, Davenport E, Ouyang J et al (2022) Pooled data analysis of the long-term treatment effects of Tolvaptan in ADPKD. Kidney Int Rep 7(5):1037\u20131048","journal-title":"Kidney Int Rep"},{"issue":"8","key":"5340_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","volume":"15","author":"A Estilo","year":"2022","unstructured":"Estilo A, Tracy L, Matthews C et al (2022) Evaluating the impact of a risk evaluation and mitigation strategy with Tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease. Clin Kidney J 15(8):1553\u20131561","journal-title":"Clin Kidney J"},{"issue":"4","key":"5340_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ekir.2024.01.020","volume":"9","author":"FJ Roca Oporto","year":"2024","unstructured":"Roca Oporto FJ, Andrades G\u00f3mez C, Montilla Cosano G, Aguilera AL, Rocha JL (2024) Prospective study on individualized dose adjustment of tolvaptan based on urinary osmolality in patients with ADPKD. Kidney Int Rep 9(4):1031\u20131039. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"5340_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.059","volume":"10","author":"LI De Rosa","year":"2025","unstructured":"De Rosa LI, Catania M, Kola K, Paolisi M, Bianca P, Manunta P, Vezzoli G, Sciarrone Alibrandi MT (2025) Refining tolvaptan dosing in ADPKD: the role of urinary biomarkers in enhancing outcomes. Kidney Int Rep 10(8):2879. https:\/\/doi.org\/10.1016\/j.ekir.2025.03.059","journal-title":"Kidney Int Rep"},{"key":"5340_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"5340_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU et al (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88:17\u201327","journal-title":"Kidney Int"},{"key":"5340_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1177\/0300060516663779","volume":"44","author":"S Kitada","year":"2016","unstructured":"Kitada S, Kikuchi S, Sonoda H et al (2016) Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure. J Int Med Res 44:1430\u20131442","journal-title":"J Int Med Res"},{"issue":"213\u2013222","key":"5340_CR13","first-page":"11","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P et al (2007) Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 50(213\u2013222):11","journal-title":"J Cardiovasc Pharmacol"},{"key":"5340_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/HJH.0000000000000423","volume":"33","author":"NJ Frenkel","year":"2015","unstructured":"Frenkel NJ, Vogt L, De Rooij SE et al (2015) Thiazide-induced hyponatraemia is associated with increased water intake and impaired urea-mediated water excretion at low plasma antidiuretic hormone and urine aquaporin-2. J Hypertens 33:627\u2013633","journal-title":"J Hypertens"},{"key":"5340_CR15","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1172\/JCI89812","volume":"127","author":"JS Ware","year":"2017","unstructured":"Ware JS, Wain LV, Channavajjhala SK et al (2017) Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. J Clin Invest 127:3367\u20133374","journal-title":"J Clin Invest"},{"key":"5340_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1751-7176.2008.08126.x","volume":"10","author":"SJ Mann","year":"2008","unstructured":"Mann SJ (2008) The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich) 10:477\u2013484","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"5340_CR17","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/ndt\/gfaa150","volume":"36","author":"BJ Kramers","year":"2021","unstructured":"Kramers BJ, Koorevaar IW, De Boer R, Hoorn EJ, Pena MJ, Gansevoort RT, Meijer E, DIPAK Consortium (2021) Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study. Nephrol Dial Transplant 36(10):1828\u20131836. https:\/\/doi.org\/10.1093\/ndt\/gfaa150","journal-title":"Nephrol Dial Transplant"},{"key":"5340_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861-","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R (2021) Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 8:777861. https:\/\/doi.org\/10.3389\/fmed.2021.777861-","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"5340_CR19","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2215\/CJN.01010211","volume":"6","author":"I Helal","year":"2011","unstructured":"Helal I, Reed B, McFann K et al (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6(10):2439\u20132443. https:\/\/doi.org\/10.2215\/CJN.01010211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"5340_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000448695-","volume":"44","author":"KL Nowak","year":"2016","unstructured":"Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B (2016) Long-term outcomes in patients with veryearly onset autosomal dominant polycystic kidney disease. Am J Nephrol 44(3):171\u2013178. https:\/\/doi.org\/10.1159\/000448695-","journal-title":"Am J Nephrol"},{"issue":"4","key":"5340_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/1440-1681.12725","volume":"44","author":"A Rahman","year":"2017","unstructured":"Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A (2017) Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol 44(4):522\u2013525. https:\/\/doi.org\/10.1111\/1440-1681.12725","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"5340_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2016.00043","volume":"3","author":"HM Salim","year":"2016","unstructured":"Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M (2016) Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med 3:43. https:\/\/doi.org\/10.3389\/fcvm.2016.00043","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"5340_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1165\/2009-0147OC","volume":"42","author":"MM Myerburg","year":"2010","unstructured":"Myerburg MM, King JD Jr., Oyster NM et al (2010) AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 42(6):676\u2013684. https:\/\/doi.org\/10.1165\/2009-0147OC","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"5340_CR24","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W et al (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol 316(1):F173\u2013F185. https:\/\/doi.org\/10.1152\/ajprenal.00462.2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"5340_CR25","doi-asserted-by":"publisher","first-page":"F1217","DOI":"10.1152\/ajprenal.00294.2016","volume":"311","author":"AT Layton","year":"2016","unstructured":"Layton AT, Laghmani K, Vallon V, Edwards A (2016) Solute transport and oxygen consumption along the nephrons: effects of Na1 transport inhibitors. Am J Physiol Renal Physiol 311(6):F1217\u2013F1229. https:\/\/doi.org\/10.1152\/ajprenal.00294.2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"5340_CR26","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00551.2017","author":"AT Layton","year":"2018","unstructured":"Layton AT, Vallon V (2018) SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00551.2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"5340_CR27","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.2147\/DMSO.S243170-","volume":"13","author":"AR Ndibalema","year":"2020","unstructured":"Ndibalema AR, Kabuye D, Wen S, Li L, Li X, Fan Q (2020) Empagliflozin protects against proximal renal tubular cell injury induced by high glucose via regulation of hypoxia-inducible factor 1-alpha. Diabetes Metab Syndr Obes 13:1953\u20131967. https:\/\/doi.org\/10.2147\/DMSO.S243170-","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"5340_CR28","doi-asserted-by":"publisher","first-page":"F1017","DOI":"10.1152\/ajprenal.00021.2020-","volume":"318","author":"J Hodrea","year":"2020","unstructured":"Hodrea J, Balogh DB, Hosszu A et al (2020) Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. Am J Physiol Renal Physiol 318(4):F1017\u2013F1029. https:\/\/doi.org\/10.1152\/ajprenal.00021.2020-","journal-title":"Am J Physiol Renal Physiol"},{"key":"5340_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DMSO.S289712","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ni L, Zhang L et al (2021) Empagliflozin regulates the AdipoR1\/p-AMPK\/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy. Diabetes Metab Syndr Obes 14:227\u2013240. https:\/\/doi.org\/10.2147\/DMSO.S289712","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"5340_CR30","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","volume":"38","author":"PB Mark","year":"2023","unstructured":"Mark PB, Sarafidis P, Ekart R et al (2023) SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant 38(11):2444\u20132455. https:\/\/doi.org\/10.1093\/ndt\/gfad112","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"5340_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.0000000725","volume":"20","author":"M Eswarappa","year":"2025","unstructured":"Eswarappa M, Madden E, Shlipak MG et al (2025) Sodium-glucose cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 20(7):940\u2013949. https:\/\/doi.org\/10.2215\/CJN.0000000725","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5340_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13730-023-00840-4","volume":"13","author":"S Nakatani","year":"2024","unstructured":"Nakatani S, Morioka F, Uedono H, Tsuda A, Mori K, Emoto M (2024) Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD. CEN Case Rep 13(4):284\u2013289. https:\/\/doi.org\/10.1007\/s13730-023-00840-4","journal-title":"CEN Case Rep"},{"issue":"4","key":"5340_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","volume":"10","author":"K Uchiyama","year":"2025","unstructured":"Uchiyama K, Kamano D, Nagasaka T et al (2025) Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan. Kidney Int Rep 10(4):1063\u20131075. https:\/\/doi.org\/10.1016\/j.ekir.2025.01.023","journal-title":"Kidney Int Rep"},{"issue":"9","key":"5340_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf269","volume":"18","author":"R Nakajima","year":"2025","unstructured":"Nakajima R, Minatoguchi S, Umeda R et al (2025) Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study. Clin Kidney J 18(9):sfaf269. https:\/\/doi.org\/10.1093\/ckj\/sfaf269","journal-title":"Clin Kidney J"},{"key":"5340_CR35","doi-asserted-by":"publisher","first-page":"sfae186","DOI":"10.1093\/ckj\/sfae186\/7695926","volume":"17","author":"M Yoshimoto","year":"2024","unstructured":"Yoshimoto M, Sekine A, Suwabe T et al (2024) Dapagliflozin treatment in patients with chronic kidney disease associ- ated with autosomal dominant polycystic kidney disease. Clin Kidney J 17:sfae186. https:\/\/doi.org\/10.1093\/ckj\/sfae186\/7695926","journal-title":"Clin Kidney J"},{"issue":"12","key":"5340_CR36","doi-asserted-by":"publisher","first-page":"088317","DOI":"10.1136\/bmjopen-2024-088317","volume":"14","author":"E Bahlmann-Kroll","year":"2024","unstructured":"Bahlmann-Kroll E, Ha\u00a8 ckl S, Kramer S et al (2024) Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. BMJ Open 14(12):088317. https:\/\/doi.org\/10.1136\/bmjopen-2024-088317","journal-title":"BMJ Open"},{"issue":"12","key":"5340_CR37","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","volume":"40","author":"RU M\u00fcller","year":"2025","unstructured":"M\u00fcller RU, Guerrot D, Chonchol M, Schmitt R, Uchiyama K, Gansevoort RT, Cornec-Le GE (2025) SGLT2 inhibition for patients with ADPKD - closing the evidence gap. Nephrol Dial Transplant 40(12):2231\u20132238. https:\/\/doi.org\/10.1093\/ndt\/gfaf061","journal-title":"Nephrol Dial Transplant"},{"key":"5340_CR38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000943","author":"MT BouAntoun","year":"2025","unstructured":"BouAntoun MT, Borghol AH, Souvalian L, Hadla M, Abboud G, Ghanem A, MunairdjyDebeh FG, Mardirossian JM, Salih M, Garimella PS, Vallon V, Chebib F (2025) SGLT2 inhibitors in\u00a0ADPKD: mechanistic insights and therapeutic promise. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000943","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5340_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","volume":"107","author":"VE Torres","year":"2025","unstructured":"Torres VE, Ahn C, Barten TRM et al (2025) KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int 107(2):234\u2013254. https:\/\/doi.org\/10.1016\/j.kint.2024.07.010","journal-title":"Kidney Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05340-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:04:54Z","timestamp":1786525494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05340-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":39,"alternative-id":["5340"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05340-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors disclose any competing interest and\/or funding in the preparation and in the submission of the present manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}